First National Bank of Omaha increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 56,660 shares of the company's stock after buying an additional 3,287 shares during the period. First National Bank of Omaha's holdings in Zoetis were worth $11,070,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares during the last quarter. Zacks Investment Management bought a new stake in Zoetis in the 3rd quarter valued at $15,754,000. Zurich Insurance Group Ltd FI raised its stake in Zoetis by 43.7% in the 3rd quarter. Zurich Insurance Group Ltd FI now owns 167,808 shares of the company's stock valued at $32,786,000 after acquiring an additional 51,030 shares during the period. National Bank of Canada FI lifted its holdings in Zoetis by 23.0% during the 3rd quarter. National Bank of Canada FI now owns 429,649 shares of the company's stock valued at $83,945,000 after purchasing an additional 80,304 shares during the last quarter. Finally, iA Global Asset Management Inc. boosted its position in Zoetis by 600.3% during the third quarter. iA Global Asset Management Inc. now owns 25,504 shares of the company's stock worth $4,983,000 after purchasing an additional 21,862 shares during the period. 92.80% of the stock is owned by institutional investors.
ZTS has been the subject of a number of research reports. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average price target of $219.00.
Read Our Latest Stock Report on ZTS
Shares of ZTS stock opened at $176.46 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a 50-day moving average of $182.07 and a 200-day moving average of $181.00. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a market cap of $79.61 billion, a P/E ratio of 33.17, a P/E/G ratio of 2.88 and a beta of 0.89.
Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis's revenue was up 11.6% on a year-over-year basis. During the same period last year, the business posted $1.36 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were given a dividend of $0.432 per share. The ex-dividend date was Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis's payout ratio is currently 32.52%.
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.